Rhumbline Advisers Has $1.04 Million Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Rhumbline Advisers reduced its stake in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 2.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 120,993 shares of the biotechnology company’s stock after selling 2,706 shares during the quarter. Rhumbline Advisers owned about 0.14% of Anavex Life Sciences worth $1,038,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its position in Anavex Life Sciences by 102.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 1,708 shares during the last quarter. Nwam LLC raised its stake in Anavex Life Sciences by 0.3% in the fourth quarter. Nwam LLC now owns 913,051 shares of the biotechnology company’s stock valued at $9,806,000 after purchasing an additional 2,575 shares in the last quarter. Vermillion Wealth Management Inc. bought a new stake in Anavex Life Sciences during the fourth quarter worth about $34,000. Ameriprise Financial Inc. increased its stake in Anavex Life Sciences by 5.1% in the fourth quarter. Ameriprise Financial Inc. now owns 66,810 shares of the biotechnology company’s stock valued at $718,000 after acquiring an additional 3,243 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its position in shares of Anavex Life Sciences by 14.4% during the 4th quarter. MetLife Investment Management LLC now owns 46,177 shares of the biotechnology company’s stock worth $496,000 after buying an additional 5,816 shares during the last quarter. Institutional investors and hedge funds own 31.55% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on AVXL shares. D. Boral Capital reaffirmed a “buy” rating and issued a $46.00 target price on shares of Anavex Life Sciences in a report on Monday, April 7th. HC Wainwright restated a “buy” rating and issued a $42.00 target price on shares of Anavex Life Sciences in a research note on Monday, April 7th.

Anavex Life Sciences Price Performance

NASDAQ AVXL opened at $9.03 on Friday. The firm has a market cap of $770.89 million, a price-to-earnings ratio of -16.42 and a beta of 0.68. Anavex Life Sciences Corp. has a 1 year low of $3.76 and a 1 year high of $14.44. The company has a fifty day moving average price of $8.46 and a 200-day moving average price of $9.04.

Anavex Life Sciences (NASDAQ:AVXL) last released its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. During the same quarter in the previous year, the firm earned ($0.13) earnings per share. On average, research analysts anticipate that Anavex Life Sciences Corp. will post -0.69 EPS for the current fiscal year.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.